BOSTON, July 21, 2011 /PRNewswire/ — PAREXEL
International Corporation (NASDAQ:
PRXL), a leading global biopharmaceutical services provider,
announced today that it has achieved a significant milestone by
completing its 100th Asian ethnobridging study, which is designed
to help biopharmaceutical companies accelerate development for the
Asia/Pacific market. PAREXEL is the innovator of the
ethnobridging study—an approach to determine safety and
tolerability, as well as possible pharmacokinetic and
pharmacodynamic differences, in target ethnic populations. The goal
of these studies is to assist PAREXEL clients in saving time and
development costs in their global early phase programs.
“PAREXEL created the ethnobridging study concept, which was
built on decades of experience in the science and practice of
ethnically-sensitive clinical programs,” said Sy Pretorius, M.D.,
M.S., M.B.A., Corporate Vice President and Worldwide Head of Early
Phase. “Our pioneering ethnobridging approach assists clients
in expediting early phase approval of compounds in certain
international markets.”
According to Dr. Pretorius, “The inclusion of Asian countries in
global drug development strategies and registration of drugs in the
Asia Pacific region have become increasingly important in recent
years. To help our clients to fast-track development in Asian
countries, PAREXEL applies leading-edge expertise through Asian
ethnobridging studies to collect Chinese, Japanese and Korean data
in the U.S. and UK for registration regionally in Asia. Achieving
the milestone of our 100th Asian ethnobridging study reinforces our
commitment to help biopharmaceutical companies prepare and execute
global development plans for emerging regions, and bring new
trea
‘/>”/>
